Skip to main content


Fig. 7 | Experimental Hematology & Oncology

Fig. 7

From: Early vs. late MRD response- and risk-based treatment intensification of childhood acute lymphoblastic leukemia: a prospective pilot study from Saudi Arabia

Fig. 7

The 5-year overall survival (a), event-free survival (b), and cumulative incidence of relapse (c) based on day 15 minimal residual disease (MRD) response: MRD negative (< 0.01%) vs. MRD positive (≥ 0.01%). Patients with day-15 MRD positive had significantly (p < 0.05) worse results for all three outcome measures. HR hazard ratio

Back to article page